Biggest News Aggregation in the World
📰 Beigene News

Page 11 - Beigene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.

BeiGene, Ltd. Expected to Post FY2027 Earnings of $5.40 Per Share (NASDAQ:BGNE)

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) – Analysts at SVB Leerink issued their FY2027 earnings per share (EPS) estimates for BeiGene in a research report issued to clients and investors on Tuesday, April 25th. SVB Leerink analyst A. Berens forecasts that the company will post earnings per share of $5.40 for the year. SVB Leerink […]
United States Johnv Oyler Xiaodong Wang Xiao Dong Wang Financial Services Group Inc Beigene Company Profile

Simplicity Solutions LLC Grows Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)

Simplicity Solutions LLC grew its position in BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 6.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,527 shares of the company’s stock after purchasing an additional 202 shares during the period. Simplicity Solutions LLC’s holdings in BeiGene were […]
Xiao Dong Wang Johnv Oyler Zurcher Kantonalbank Zurich Cantonalbank Xiaodong Wang Colony Group Profund Advisors
Source: wkrb13.com

Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma

The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Mark Lanasa Solid Tumors Cancers Symposium Arkenauh T Tislelizumab Plus Chemotherapy Patients With Advanced Unresectable Or Metastatic Gastric Gastroesophageal Junction Adenocarcinoma

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BeiGene, Ltd. (NASDAQ:BGNE) Given Average Rating of "Moderate Buy" by Analysts

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has been given an average rating of “Moderate Buy” by the nine brokerages that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have […]
United States Xiaodong Wang Xiao Dong Wang Johnv Oyler Financial Services Group Inc Ci Investments Inc
Source: wkrb13.com

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

MapKure, LLC, BeiGene, Ltd. , and SpringWorks Therapeutics, Inc. , today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective... | April 17, 2023
Memorial Sloan Kettering Cancer Center New York United States United Kingdom Lusong Luo Saqib Islam

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

BeiGene, Ltd. , and SpringWorks Therapeutics, Inc. , today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in... | April 17, 2023
United States United Kingdom Lusong Luo Saqib Islam European Commission American Association For Cancer Research

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science